Cyclacel Pharmaceuticals (CYCC) Stock Forecast & Price Target

$0.35 +0.01 (+2.91%)

(As of 11/26/2024 ET)

Cyclacel Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 3 Analyst Ratings

Sell
0

Hold
2

Buy
1

Based on 3 Wall Street analysts who have issued ratings for Cyclacel Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 2 have given a hold rating, and 1 has given a buy rating for CYCC.

Consensus Price Target

$11.00
3,007.34% Upside

According to the 3 analysts' twelve-month price targets for Cyclacel Pharmaceuticals, the average price target is $11.00. The highest price target for CYCC is $11.00, while the lowest price target for CYCC is $11.00. The average price target represents a forecasted upside of 3,007.34% from the current price of $0.35.

Get the Latest News and Ratings for CYCC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cyclacel Pharmaceuticals and its competitors.

CYCC Analyst Ratings Over Time

Type	Current Forecast 11/28/23 to 11/27/24	1 Month Ago 10/29/23 to 10/28/24	3 Months Ago 8/30/23 to 8/29/24	1 Year Ago 11/28/22 to 11/28/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$11.00	$11.00	$11.00	$120.00
Forecasted Upside	3,007.34% Upside	1,471.43% Upside	957.69% Upside	2,582.76% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Buy

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

CYCC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CYCC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cyclacel Pharmaceuticals Stock vs. The Competition

Type	Cyclacel Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.33	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	3,007.34% Upside	25,264.12% Upside	6.71% Upside
News Sentiment Rating	Neutral News See Recent CYCC News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/23/2024	Roth Capital 3 of 5 stars	J. Aschoff Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/3/2024	Roth Mkm 1 of 5 stars		Lower Target	Buy ➝ Buy	$21.00 ➝ $11.00	+384.58%
12/19/2023	Brookline Capital Management 2 of 5 stars	K. Dolliver Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
3/7/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$150.00 ➝ $120.00	+997.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:32 AM ET.

CYCC Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Cyclacel Pharmaceuticals is $11.00, with a high forecast of $11.00 and a low forecast of $11.00.
: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CYCC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CYCC, but not buy additional shares or sell existing shares.
: According to analysts, Cyclacel Pharmaceuticals's stock has a predicted upside of 3,007.34% based on their 12-month stock forecasts.
: Over the previous 90 days, Cyclacel Pharmaceuticals's stock had 1 downgrade by analysts.
: Cyclacel Pharmaceuticals has been rated by research analysts at Roth Capital in the past 90 days.
: Analysts like Cyclacel Pharmaceuticals less than other "medical" companies. The consensus rating for Cyclacel Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CYCC compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)

Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?

Click Here For Your Free Guide

This page (NASDAQ:CYCC) was last updated on 11/27/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cyclacel Pharmaceuticals (CYCC) Stock Forecast & Price Target